Scientific publications

CS1-related Epigenetic modulation and HDAC inhibition CS585-related

CS1-related

Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial

Raymond L. Benza, Marc A. Simon, Selim R. Krim, H. James Ford, Tatiane Abreu Dall-Agnol, Sandhya Murthy, Evelyn Horn, Jason L. Guichard. 4th Balthic Conference on May 9, 2025. [Abstract Book, page 11]

Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study

Raymond Benza, Niklas Bergh, Philip Adamson, Björn Dahlöf. PVRI congress 2022.

A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate

Niklas Bergh, Jan-Peter Idström, Henri Hansson, Jonas Faijerson-Säljö, Björn Dahlöf.
Journal of Cardiology and Vascular Medicine 2019 Volume 5: 1-12.

Epigenetic modulation and HDAC inhibition

Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.

João Pedro Ferreira, Bertram Pitt, Faiez Zannad. The Lancet Healthy Longevity, Volume 2, Issue 6, 2021, pages e371-e379, ISSN 2666-7568, doi.org/10.1016/S2666-7568(21)00061-1.

CS585-related

CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding

Sylviane Lambert, Reheman Adili, Pooja Yalavarthi, Nicole Rhoads, Björn Dahlöf, Andrew White, Niklas Bergh, Michael Holinstat. HemaSphere, 2022; 6:S3.

CS585 is a novel orally available prostacyclin receptor agonist with sustained in vivo inhibition of platelets and thrombosis formation in mouse without increased risk of bleeding

Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Adriana Yamaguchi, Michael Holinstat, Niklas Bergh, Björn Dahlöf. ACC.23/WCC Congress 2023.